Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Questcor To Acquire BioVectra | Contract Pharma

What are you searching for?

Sign in
Breaking News

Questcor To Acquire BioVectra

Gains API manufacturing capabilities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Questcor Pharmaceuticals has signed a definitive agreement to acquire all issued and outstanding shares of BioVectra Inc., for an upfront payment of $50.6 million. BioVectra provides contract manufacturing services to the global pharmaceutical and biotechnology industry, and manufactures APIs, chemical intermediates, and bioprocessing reagents.
 
BioVectra has been Questcor’s manufacturing partner for the API in Questcor’s H.P. Acthar Gel (repository corticotropin injection) for the past 10 years. BioVectra will continue to operate independently in Prince Edward Island, under its existing management team and Questcor will support the continued growth of BioVectra’s business.
 
BioVectra’s capabilities include synthetic organic chemistry, natural extraction of bioactive compounds from plant and animal-based biomass sources, PEGylation and conjugation chemistry, and fermentation of a variety of molecule types. BioVectra employs approximately 180 people including chemists, engineers and technicians, and had sales of approximately $28 million in its last fiscal year ended August 31, 2012, up 15% from 2011.
 
“We are excited to join efforts with BioVectra as we look to diversify our revenue,” said Don M. Bailey, president and chief executive officer of Questcor. “This action puts us in a better position to meet the continuing growth in demand for Acthar, brings to our company a broader depth of technical and scientific expertise, and provides us with a platform for potential international expansion.”
 
“We pride ourselves on being a strategic partner, forging long-term relationships with our clients and utilizing our proven technical skills to serve our clients’ business needs,” said Ron Keefe, chief executive officer of BioVectra. “Questcor has been an important long term partner and we look forward to further building our relationship.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics